Hobit and human effector T-cell differentiation: The beginning of a long journey

被引:17
|
作者
Braun, Julian [1 ]
Frentsch, Marco [1 ]
Thiel, Andreas [1 ]
机构
[1] Charite, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Regenerat Immunol & Aging, D-13353 Berlin, Germany
关键词
CD8(+) T cell; Effector cell; Homolog of Blimp-1 in T cells; Human; T-cell differentiation; Transcription factor; MEMORY CD8(+); SELECTIVE EXPRESSION; CYTOMEGALOVIRUS; RECEPTOR; LYMPHOCYTES; EXHAUSTION; INFECTION; SUBSETS; CD4(+); GENES;
D O I
10.1002/eji.201545959
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Besides growing plants, eating a lot, and drinking beer, Tolkien's Hobbits enjoy maintaining a quiet state. Regarding the latter, the name chosen for a recently discovered transcription factor seems to be unintentionally appropriate. The zinc finger protein ZNF683 was originally named Hobit for Homolog of Blimp-1 in T cells. In this issue of the European Journal of Immunology, Braga etal. [Eur. J. Immunol. 2015. 45: 2945-2958] demonstrate that in humans, Hobit is almost exclusively expressed in effector T cells, in particular in quiescent and long-lived effector-type CD8(+) T cells. Hobit may initially appear as another player in the quest for transcription factors guiding T-cell differentiation; the discoveries of T-bet, Eomes, Blimp-1, and others have significantly contributed to our understanding of how this process is tightly regulated. However, Hobit may be specialthe currently available results suggest substantial differences in Hobit's regulatory functions between mice and humans, such as expression patterns and IFN- regulation. And it may turn out that Hobit's function in human T cells is highly adapted to lifelong, periodic challenges with varying, physiological doses of pathogens. Thus, the new study about Hobit in human T cells may be the beginning of a long journey.
引用
收藏
页码:2762 / 2765
页数:4
相关论文
共 50 条
  • [21] Mouse Hobit is a homolog of the transcriptional repressor Blimp-1 that regulates NKT cell effector differentiation
    Klaas P J M van Gisbergen
    Natasja A M Kragten
    Kirsten M L Hertoghs
    Felix M Wensveen
    Stipan Jonjic
    Jörg Hamann
    Martijn A Nolte
    Rene A W van Lier
    Nature Immunology, 2012, 13 : 864 - 871
  • [22] THYMUS, T-CELL DIFFERENTIATION AND THE T-CELL SYSTEM
    JENKINSON, EJ
    ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, 1982, 149 : 237 - 240
  • [23] HUMAN T-CELL DIFFERENTIATION ANTIGENS AND CORRELATION OF THEIR EXPRESSION WITH VARIOUS MARKERS OF T-CELL MATURATION
    BOUMSELL, L
    BERNARD, A
    COPPIN, H
    RICHARD, Y
    PENIT, C
    ROUGET, P
    LEMERLE, J
    DAUSSET, J
    JOURNAL OF IMMUNOLOGY, 1979, 123 (05): : 2063 - 2067
  • [24] Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients
    Gannon, Philippe O.
    Baumgaertner, Petra
    Huber, Alexandre
    Iancu, Emanuela M.
    Cagnon, Laurene
    Maillard, Samia Abed
    Maby-El Hajjami, Helene
    Speiser, Daniel E.
    Rufer, Nathalie
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3285 - 3296
  • [25] The foundations of γδ T-cell effector fate
    Sarah Allan
    Nature Reviews Immunology, 2008, 8 : 575 - 575
  • [26] Regulator and effector functions of T-cell subsets in human Leishmania infections
    Kemp, M
    APMIS, 1997, 105 : 5 - 33
  • [27] EFFECTOR T-CELL REPERTOIRE SELECTION IN HUMAN ALLOGRAFT-REJECTION
    FINN, OJ
    MICELI, MC
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 346 - 348
  • [28] Histone acetyltransferase CBP is critical for conventional effector and memory T-cell differentiation in mice
    Piccirillo, Ann R.
    Cattley, Richard T.
    D'Cruz, Louise M.
    Hawse, William F.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (07) : 2397 - 2406
  • [29] TRANSCRIPTIONAL AND PROLIFERATIVE DEFECTS IN T-CELL EFFECTOR DIFFERENTIATION WITH AGING ERODE IMMUNE DEFENSE
    Nikolich-Zugich, J.
    GERONTOLOGIST, 2011, 51 : 267 - 267
  • [30] Peripheral T-Cell Lymphoma: The Beginning of the End of the Beginning Preface
    Jacobsen, Eric D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (02) : XIII - XIV